ARTV
Artiva Biotherapeutics, Inc.Company with tickers: ARTV
CIK
1817241
CUSIP
04317A107
Shares Outstanding
48,588,198
Website
https://www.artivabio.com
Investor Relations
https://investors.artivabio.com/overview/default.aspx
13F Activity (30d)
4 filings
3 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $24,430,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Research & Development | $19,312,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Operating Income | $-24,430,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Net Income | $-23,516,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Basic) | $-0.95 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Diluted) | $-0.95 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |